Publication | Open Access

Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG–0803)

Second-line TreatmentMedicinePathologyPhase Ii StudyAsymptomatic Brain MetastasesBronchial NeoplasmCancer TreatmentOncologyRadiation OncologyLung Cancer